Posted by Social Science Research Network
Innovation, Litigation, and New Drugs Ramsi Woodcock (Georgia State University)
Abstract: The study of patent settlements that specify the date at which a challenger may bring a competing product to market (“entry settlements”) has not taken innovation into account. I adapt the standard optimal patent life model to account for innovation in considering the effect of entry settlements on consumer value. I determine the maximum strengthening of a patent through settlement that does not harm consumers, calibrate it with drug market data, and conclude that, for patents weaker than 80.3%, drug patent strengthening of more than 42.5 percentage points, or any agreement to enter at patent expiry, harms consumers.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI